MBRX — Moleculin Biotech Share News
0.000.00%
Last trade - 00:00Moleculin Biotech rises as cancer drug shows no heart damage in trials
Brief: Moleculin Reports Independent Assessment Confirms No Cardiotoxicity Of Annamycin In 90 Subjects
Brief: Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs
Brief: Moleculin Biotech Regains Nasdaq Listing Compliance
Brief: Moleculin Announces Positive Phase 1 Data For WP1066 In Pediatric Brain Tumors
Brief: Moleculin Announces New Annamycin Collaboration In Brain Tumors
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:50 PM
U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurers
U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, Grindr
Moleculin Biotech falls after reverse stock split move
U.S. STOCKS ON THE MOVE-TransDigm, Citigroup, Cisco Systems
U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners
Moleculin gains after UNC partnership to study new pancreatic cancer treatment
U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture Global
Moleculin rises after UNC partnership to study new pancreatic cancer treatment